Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol et autres
0 citations
Ian McCaffery
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
104Publications signalées
4049Citations signalées
0Affiliations récentes
Les domaines associés
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchAdenosine and Purinergic SignalingCancer, Hypoxia, and Metabolism
Les publications récentes
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol et autres
0 citations
Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
Stephen B. Willingham, Po Y. Ho, Andrew Hotson, Craig L. Hill et autres
0 citations
Supplementary Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
Stephen B. Willingham, Po Y. Ho, Andrew Hotson, Craig L. Hill et autres
0 citations
Supplementary Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
Stephen B. Willingham, Po Y. Ho, Andrew Hotson, Craig L. Hill et autres
0 citations
Data from A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
Stephen B. Willingham, Po Y. Ho, Andrew Hotson, Craig L. Hill et autres
0 citations
Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol et autres
0 citations
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol et autres
0 citations
Supplementary Figure 4 from Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej et autres
0 citations
Supplementary Figure 3 from Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej et autres
0 citations
Supplementary Methods, Figure Legends from Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej et autres
0 citations
Supplementary Figure 1 from Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.